Alaunos Therapeutics, Inc. (TCRT)
NCM · Healthcare · Biotechnology
$1.51
-3.21%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$3.8M
Shares Outstanding
2.5M
P/S (TTM)
1,279x
Exchange
NCM
Currency
USD
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 3K | 0.00 | 0.00 |
| Operating Income | (1.2M) | (907K) | (1.0M) | (952K) |
| Net Income | (1.2M) | (893K) | (1.0M) | (952K) |
| Diluted EPS | $-0.55 | N/A | $-0.59 | $-0.41 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.9M | 5K | 10K | 5K |
| Operating Income | (35.2M) | (28.5M) | (4.8M) | (4.2M) |
| Net Income | (37.7M) | (35.1M) | (4.7M) | (4.2M) |
| Diluted EPS | $-25.50 | $-21.97 | $-2.92 | $-2.20 |